Upfront stereotactic radiosurgery for large posterior fossa metastases: a multicenter evaluation of clinical outcomes - Summary - MDSpire

Upfront stereotactic radiosurgery for large posterior fossa metastases: a multicenter evaluation of clinical outcomes

  • By

  • Ben-Shoshan, Ariel

  • Heymann, Sami

  • Asprilla, José

  • Kelmer, Paz

  • Moscovici, Samuel

  • Hillman, Yair

  • Weizman, Noam

  • Bohbot, Rotem

  • Wohl, Anton

  • Cohen, Zvi R.

  • Lawrence, Yaacov R.

  • Wygoda, Marc

  • Shoshan, Yigal

  • Kaisman-Elbaz, Tehila

  • Falick Michaeli, Tal

  • March 2, 2026

  • 0 min

Share

Objective:

To evaluate the clinical outcomes of upfront stereotactic radiosurgery (SRS) for large cerebellar metastases greater than 5 cm³, highlighting its potential impact on treatment strategies.

Key Findings:
  • SRS demonstrated favorable local control rates for large cerebellar metastases, particularly when compared to traditional surgical approaches.
  • Patients treated with SRS had a median overall survival of 12 months, aligning with previous studies.
  • Complications from SRS were generally lower compared to surgical resection, emphasizing its non-invasive nature.
Interpretation:

Upfront SRS may provide a viable non-invasive treatment option for patients with large cerebellar metastases, particularly those at high risk for surgical complications, suggesting a shift in treatment paradigms.

Limitations:
  • Retrospective design may introduce selection bias and limit the robustness of the findings.
  • Limited generalizability due to the specific patient population and treatment centers, along with potential biases in data collection and analysis.
Conclusion:

SRS is a promising alternative to surgery for large cerebellar metastases, offering effective local control with potentially lower complication rates, warranting further investigation in broader clinical settings.

Original Source(s)

Upfront stereotactic radiosurgery for large posterior fossa metastases: a multicenter evaluation of clinical outcomes

  • by Ben-Shoshan, Ariel, Heymann, Sami, Asprilla, José, Kelmer, Paz, Moscovici, Samuel, Hillman, Yair, Weizman, Noam, Bohbot, Rotem, Wohl, Anton, Cohen, Zvi R., Lawrence, Yaacov R., Wygoda, Marc, Shoshan, Yigal, Kaisman-Elbaz, Tehila, Falick Michaeli, Tal

  • March 2, 2026

Related Content

Second Primary Cancer Risk Shifts Over Time

US registry study finds overall declines but rising risk in lung, melanoma, and older survivor groups

Context-dependent functions of ALKBH5: a mechanistic framework linking cellular stress responses, immune regulation, viral infection, and therapeutic vulnerabilities

Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors